Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates

Analytical Biochemistry

Volumn 393, Issue 2, 2009, Pages 205-214

  Ghosh, Gargi ^a   Lee, Andrew G ^a   Palecek, Sean P ^a  

^a University of Wisconsin Madison   (United States)

Author keywords

EGFR inhibitors; EGFR tyrosine kinase; Polyacrylamide; Protein array

Indexed keywords

AMIDES; AMINO ACIDS; CELL CULTURE; DIAGNOSIS; DISEASES; ENZYMES; HYDROGELS; PATIENT TREATMENT; POLYACRYLATES; TUMORS;

ACRYLAMIDE COPOLYMERS; EPIDERMAL GROWTH FACTOR RECEPTORS; GLUTATHIONE S-TRANSFERASES; POLYACRYLAMIDE HYDROGELS; PREDICTIVE DIAGNOSTICS; PROTEIN ARRAYS; TYROSINE KINASE; TYROSINE KINASE INHIBITOR;

CELLS;

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLUTATHIONE TRANSFERASE; POLYACRYLAMIDE GEL;

ARTICLE; CANCER CELL; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROGEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN IMMOBILIZATION; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; UPREGULATION;

EID: 68349131622     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2009.07.002     Document Type: Article

References (33)

1. In: Boyle P., and Levin B. (Eds). World Cancer Report (2008), International Agency for Research on Cancer, Lyon, France
2. Madhusudan S., and Ganesan T.S. Tyrosine kinase inhibitors in cancer therapy. Clin. Biochem. 37 (2004) 618-635
3. Laskin J.J., and Sandler A.B. Epidermal growth factor receptor: a promising target in solid tumors. Cancer Treat. Rev. 30 (2004) 1-17
4. Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur. J. Cancer 37 (2001) S3-S8
5. Vlahovic G., and Crawford J. Activation of tyrosine kinases in cancer. Oncologist 8 (2003) 531-538
6. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J.M., Salonga D., Holscher A.H., and Danenberg P.V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 7 (2001) 1850-1855
7. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
8. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2 (2005) 1-11
9. Wosikowski K., Schuurhuis D., Kops G.J., Saceda M., and Bates S.E. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res. 3 (1997) 2405-2414
10. Selvaggi G., Novello S., Torri V., Leonardo E., De Giuli P., Borasio P., Mossetti C., Ardissone F., Lausi P., and Scagliotti G.V. Epidermal growth factor overexpression correlates with poor prognosis in completely resected non-small cell lung cancer. Ann. Oncol. 15 (2004) 28-32
11. Nicholson R.I., Gee J.M.W., and Harper M.E. EGFR Cancer prognosis. Eur. J. Cancer 37 (2001) 9-15
12. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 (2002) 2-8
13. Ohsaki Y., Tanno S., Fujita Y., Toyoshima E., Fujiuchi S., Nishigaki Y., Ishida S., Nagase A., Miyokawa N., Hirata S., and Kikuchi K. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep. 7 (2000) 603-607
14. Mendelsohn J., and Baselga J. EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
15. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., Albain K.S., Cella D., Wolf M.K., Averbuch S.D., Ochs J.J., and Kay A.C. Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290 (2003) 2149-2158
16. Brueggemeier S.B., Stephen D.W., Kron S.J., and Palecek S.P. Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates. Biomacromolecules 6 (2005) 2765-2775
17. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
18. Lee J.W., Soung Y.H., Kim S.Y., Nam H.Y., Park W.S., Nam S.W., Kim M.S., Sun D., Lee Y.S., Jang J.J., Lee J.Y., Yoo N.J., and Lee S.H. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11 (2004) 2879-2882
19. Fazioli F., Minichiello L., Matoskova B., Wong W.T., and di Fiore P.P. Eps15, a novel tyrosine kinase substrate, exhibits transforming activity. Mol. Cell. Biol. 13 (1993) 5814-5828
20. Carbone R., Fre S., Iannolo G., Belleudi F., Mancini P., Pelicci P.G., Torrisi M.R., and di Fiorre P.P. Eps15 and Eps15R are essential components of the endocytic pathway. Cancer Res. 57 (1997) 5498-5504
21. Benmarah A., Lamaze C., Begue B., Schmid S.L., Dautry-Varsat A., and Cerf-Bensussan N. AP-2/Eps15 interaction is required for receptor-mediated endocytosis. J. Cell Biol. 140 (1998) 1055-1062
22. Benmarah A., Poupon V., Cerf-Bensussan N., and Dautry-Varsat A. Mapping of Eps15 domains involved in its targeting to clathrin-coated pits. J. Biol. Chem. 275 (2000) 3288-3295
23. Confalonieri S., Salcini A.E., Puri C., Tacchetti C., and di Fiore P.P. Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J. Cell Biol. 150 (2000) 905-911
24. Brueggemeier S.B., Kron S.J., and Palecek S.P. Use of protein-acrylamide copolymer hydrogels for measuring protein concentration and activity. Anal. Biochem. 329 (2004) 180-189
25. Naruse I., Ohmori T., Ao Y., Fukumoto H., Kuroki T., Mori M., Saijo N., and Nishio K. Antitumor activity of the selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR expressing multidrug resistant cell line in vitro and in vivo. Intl. J. Cancer 98 (2002) 310-315
26. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., and Fukami Y. Genistein, A specific inhibitor of tyrosine-specific protein kinases. J. Cell Biol. 262 (1987) 5592-5595
27. van Delft S., Schumacher C., Hage W., Verkleij A.J., and van Bergen en Henegouwen P.M.P. Association and colocalization of Eps15 with adaptor protein-2 and clathrin. J. Cell Biol. 136 (1997) 811-821
28. Arteaga C.L. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 7 (2002) 31-39
29. Mandic R., Eikelkamp N., Peldszus R., Sadowski M., Sesterhenn A.M., Dunne A.A., and Werener J.A. Variations of EGF-R expression in squamous cell carcinoma of head and neck region. Anticancer Res. 21 (2001) 3413-3418
30. Kumar R.R., Meenakshi A., and Sivakumar N. Enzyme immunoassay of human epidermal growth factor (hEGFR). Hum. Antibodies 10 (2001) 143-147
31. Kobayashi S., Ji H., Yuza Y., Meyerson M., Wong K.-K., Tenen D.G., and Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of epidermal growth factor receptor. Cancer Res. 65 (2005) 7096-7101
32. Costa D.B., Schumer S.T., Tenen D.G., and Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying L747S or T790M secondary mutations. J. Clin. Oncol. 26 (2008) 1182-1184
33. Choong N.W., Dietrich S., Seiwert T.Y., Tretiakova M.S., Nallasura V., Davies G.C., Lipkowitz S., Husain A.N., Salgia R., and Ma P.C. Gefitinib response of erlotinib-refractory lung cancer involving meninges: role of EGFR mutation. Nat. Clin. Pract. Oncol. 3 (2006) 50-57